A Phase 1 interventional study of AVT03 and Denosumab in This is a Phase I Study Conducted in Healthy Volunteers, sponsored by Alvotech Swiss AG. Completed at 3 sites in 3 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study has been designed as a randomized, double-blind, parallel-group study and in healthy adult male subjects of age 28 years to 55 years old. The study will assess the PK, safety and tolerability of AVT03 compared to US-Xgeva when administered as a single 120 mg SC dose
The study will consist of screening period, a 196 day (28 weeks) treatment and assessment period, and an End of Study (EOS) visit on week 32 on Day 196. Subjects will undertake a screening visit between Day -28 and Day -1 to determine their eligibility for the study. Subjects who meet the eligibility criteria will be admitted to the study site on the day prior to dosing (Day -1), during which their continued eligibility will be assessed up to Day 1 prior to dosing. On Day 1, eligible subjects will be randomized and will receive a single dose of 120mg AVT03 or 120mg Xgeva as subcutaneous injection.
Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AVT03 is the proposed biosimilar for Xgeva (denosumab). Subjects in this arm will receive a single 120mg dose of AVT03 as a subcutaneous injection
Biological: AVT03
Xgeva (denosumab) is the proposed active comparator for AVT03. Subjects in this arm will receive a single 120mg dose of Xgeva (denosumab) as a subcutaneous injection
Biological: Denosumab
Co-primary PK Endpoint Cmax: Maximum Serum Concentration
Samples will be collected for measurement
Time frame: Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study
Co-primary PK endpoint_AUC0-t: Area Under the Serum Concentration-time Curve up to Time t, Where t is the Last Time Point With a Concentration Above the Lower Limit of Quantitation
Samples will be collected for measurement
Time frame: Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study
PK_ AUC0-inf: Comprised of AUC0-t and AUC Extrapolated From Time t to Time Infinity.
Samples will be collected for measurement
Time frame: Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study
Safety Incidence, Nature and Severity of Adverse Events.
Time frame: Day 1(week 1) to Day 196 (week 28)]
Immunogenicity Presence of ADAs and Presence of nAbs Against AVT03 and Xgeva
Samples will be collected for measurement
Time frame: Day 1, Day 8, Day 15, Day 29, Day 57, Day 71, Day 112, Day 141, Day 196/EoS
| Milestone | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| Started | 104 | 104 |
| Completed | 103 | 98 |
| Not completed | 1 | 6 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Death | 0 | 1 |
Samples will be collected for measurement
| ng/mL | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| Co-primary PK Endpoint Cmax: Maximum Serum Concentration | 12761.4 ± 34 | 12259.8 ± 32 |
Samples will be collected for measurement
| ng·h/mL | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| Co-primary PK endpoint_AUC0-t: Area Under the Serum Concentration-time Curve up to Time t, Where t is the Last Time Point With a Concentration Above the Lower Limit of Quantitation | 15501387.9 ± 27 | 14366056.2 ± 29 |
Samples will be collected for measurement
| ng·h/mL | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| PK_ AUC0-inf: Comprised of AUC0-t and AUC Extrapolated From Time t to Time Infinity. | 15559245.8 ± 28 | 14555779.3 ± 29 |
| participants | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| Any TEAE | 66 | 67 |
| TESAEs | 1 | 3 |
Samples will be collected for measurement
| Participants | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| Binding (ADA) | 104 | 102 |
| Neutralizing Antibodies | 41 | 43 |
Collected over All AEs/SAEs were recorded from the time of signing the ICF until the end of the subject's participation in the study, up to 32 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Arm AVT03 120mg | 0/104 (0%) | 1/104 (1%) | 66/104 (63.5%) |
| Active Comparator Xgeva 120mg | 1/104 (1%) | 3/104 (2.9%) | 67/104 (64.4%) |
| Event | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| PneumoniaInfections and infestations | 0/104 | 1/104 |
| Small bowel obstructionGastrointestinal disorders | 1/104 | 0/104 |
| HepatitisHepatobiliary disorders | 0/104 | 1/104 |
| Alcohol use disorderGeneral disorders | 0/104 | 1/104 |
| Event | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/104 | 11/104 |
| Upper respiratory tract infectionInfections and infestations | 11/104 | 10/104 |
| HeadacheNervous system disorders | 10/104 | 7/104 |
| Blood creatine phosphokinase increasedInvestigations | 8/104 | 5/104 |
| InfluenzaInfections and infestations | 5/104 | 6/104 |
| NeutropeniaBlood and lymphatic system disorders | 5/104 | 1/104 |
| Blood pressure increasedInvestigations | 5/104 | 2/104 |
| DiarrhoeaGastrointestinal disorders | 3/104 | 4/104 |
| Injection site reactionGeneral disorders | 3/104 | 4/104 |
| COVID-19Infections and infestations | 1/104 | 4/104 |
Participants were healthy males aged 28 to 55 years.
| Age, Continuous(years) | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg | Total |
|---|---|---|---|
| Mean | 36.5 ± 6.72 | 38.1 ± 7.08 | 37.3 ± 6.94 |
| Sex: Female, Male(Participants) | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 104 | 104 | 208 |
| Race/Ethnicity, Customized(Participants) | Experimental Arm AVT03 120mg | Active Comparator Xgeva 120mg | Total |
|---|---|---|---|
| Asian (Japanese) | 12 | 12 | 24 |
| Black or African American | 28 | 24 | 52 |
| Caucasian/White | 64 | 68 | 132 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Apr 2024, 8 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AVT03
Alvotech Swiss AG